Saxagliptin

Prescrire International

Volumn 20, Issue 113, 2011, Pages 33-37

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; METFORMIN; PIOGLITAZONE; PLACEBO; RIFAMPICIN; ROSIGLITAZONE; SAXAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN; ADAMANTANE; ANTIDIABETIC AGENT; DIPEPTIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DRUG DERIVATIVE;

AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONSTIPATION; DEPRESSION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; EDEMA; ERYTHEMA; EUROPEAN UNION; FATIGUE; FLU LIKE SYNDROME; FRACTURE; GASTROINTESTINAL DISEASE; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPOGLYCEMIA; LYMPHOCYTOPENIA; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREATITIS; PERIPHERAL EDEMA; POSTMARKETING SURVEILLANCE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; REVIEW; RISK BENEFIT ANALYSIS; RISK MANAGEMENT; SIDE EFFECT; SINUSITIS; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; TREATMENT RESPONSE; ARTICLE; COMPARATIVE STUDY; DRUG APPROVAL; DRUG INTERACTION;

ADAMANTANE; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG APPROVAL; DRUG INTERACTIONS; EUROPEAN UNION; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 79851495315     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. Prescrire Editorial Staff "Sitagliptin" Prescrire Int 2008; 17 (93): 12-15.
2. Prescrire Editorial Staff "Vildagliptin and vildagliptin + metformin" Prescrire Int 2008; 17 (97): 188.
3. European Commission "Summary of Product Characteristics - Onglyza" 1 October 2009: 29 pages.
4. U.S. Food and Drug Administration - Center for Drug Evaluation and Research "Application number: NDA 22-350. Statistical review" 23 January 2009: 73 pages.
5. U.S. Food and Drug Administration - Center for Drug Evaluation and Research "Application number: NDA 22-350. Medical review" 7 June 2009: 308 pages.
6. U.S. Food and Drug Administration - Center for Drug Evaluation and Research "Application number: NDA 22-350. Summary review" 29 July 2009: 21 pages.
7. European Medicines Agency - CHMP "Assessment report for Onglyza Scientific discussion n° EMEA/H/C/001039": 57 pages; posted on the EMA website on 27 December 2009.
8. 8- Rosenstock J et al. "Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes" Diabetes Obes Metab 2008; 10 (5): 376-386. (Pubitemid 351524285)
9. Chacra AR et al. "Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial" Int J Clin Pract 2009; 63 (9): 1395-1406.
10. Jadzinsky M et al. "Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial" Diabetes Obes Metab 2009; 11 (6): 611-622.
11. HAS - Commission de la transparence "Avis- Onglyza" 2 December 2009: 18 pages.
12. Prescrire Rédaction "4-1. Patients diabétiques" Rev Prescrire 2010; 30 (326 suppl. interactions médicamenteuses).
13. Prescrire Editorial Staff "Sitagliptin: too many cases of pancreatitis" Prescrire Int 2010; 19 (106): 75.
14. Prescrire Editorial Staff "Sitagliptin: serious allergies" Prescrire Int 2009; 18 (101): 123.
15. AstraZeneca "Clinical study protocol - SAVOR: saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus" October 2009: 149 pages.
16. U.S. Food and Drug Administration "Application number: NDA 22-350. Approval letter" 31 July 2009: 8 pages.